An overview of the role of monoamine oxidase-B in Parkinson’s disease: implications for neurodegeneration and therapy

Praveen Kumar Chandra Sekar, Sheena Mariam Thomas, Ramakrishnan Veerabathiran
{"title":"An overview of the role of monoamine oxidase-B in Parkinson’s disease: implications for neurodegeneration and therapy","authors":"Praveen Kumar Chandra Sekar, Sheena Mariam Thomas, Ramakrishnan Veerabathiran","doi":"10.37349/ent.2024.00085","DOIUrl":null,"url":null,"abstract":"Parkinson’s disease (PD) is a neurodegenerative disorder characterized by both non-motor and motor symptoms, due to the loss of dopamine-producing neurons in the brain. Monoamine oxidase-B (MAO-B) inhibitors are essential in the treatment of PD, as they increase dopamine levels and could potentially slow down the progression of the disease. MAO-B inhibitors block the ability of the enzyme to degrade dopamine in the brain. MAO-B inhibitors work by inhibiting this enzyme, which raises dopamine levels and helps reduce motor symptoms, such as akinesia and stiffness in the muscles. In addition to their impact on dopamine levels, MAO-B inhibitors may possess neuroprotective properties. Research indicates that these inhibitors can shield neurons from the harmful byproducts of dopamine breakdown, such as dihydroxy acetaldehyde and hydrogen peroxide. This neuroprotective effect could potentially slow the progression of PD and protect against neuronal damage. MAO-B inhibitors are effective in treating both advanced and early stages of PD. They are recommended as initial treatments for individuals with early PD and can also be used as supplementary therapy in advanced PD to assist in managing motor complications. Additionally, MAO-B inhibitors have shown promise for the treatment of non-motor symptoms of PD, such as fatigue and sleep disturbances. MAO-B inhibitors are an important class of drugs for the treatment of PD, offering both symptomatic relief and potential disease-modifying effects. The goal of ongoing research and development of MAO-B inhibitors is to enhance their safety and selectivity profiles, which could lead to improved treatment approaches for PD and other neurodegenerative disorders.","PeriodicalId":502664,"journal":{"name":"Exploration of Neuroprotective Therapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Exploration of Neuroprotective Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37349/ent.2024.00085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by both non-motor and motor symptoms, due to the loss of dopamine-producing neurons in the brain. Monoamine oxidase-B (MAO-B) inhibitors are essential in the treatment of PD, as they increase dopamine levels and could potentially slow down the progression of the disease. MAO-B inhibitors block the ability of the enzyme to degrade dopamine in the brain. MAO-B inhibitors work by inhibiting this enzyme, which raises dopamine levels and helps reduce motor symptoms, such as akinesia and stiffness in the muscles. In addition to their impact on dopamine levels, MAO-B inhibitors may possess neuroprotective properties. Research indicates that these inhibitors can shield neurons from the harmful byproducts of dopamine breakdown, such as dihydroxy acetaldehyde and hydrogen peroxide. This neuroprotective effect could potentially slow the progression of PD and protect against neuronal damage. MAO-B inhibitors are effective in treating both advanced and early stages of PD. They are recommended as initial treatments for individuals with early PD and can also be used as supplementary therapy in advanced PD to assist in managing motor complications. Additionally, MAO-B inhibitors have shown promise for the treatment of non-motor symptoms of PD, such as fatigue and sleep disturbances. MAO-B inhibitors are an important class of drugs for the treatment of PD, offering both symptomatic relief and potential disease-modifying effects. The goal of ongoing research and development of MAO-B inhibitors is to enhance their safety and selectivity profiles, which could lead to improved treatment approaches for PD and other neurodegenerative disorders.
概述单胺氧化酶-B 在帕金森病中的作用:对神经变性和治疗的影响
帕金森病(Parkinson's disease,PD)是一种神经退行性疾病,由于大脑中产生多巴胺的神经元缺失,导致患者出现非运动症状和运动症状。单胺氧化酶-B(MAO-B)抑制剂对治疗帕金森病至关重要,因为它们能提高多巴胺水平,并有可能减缓疾病的进展。MAO-B抑制剂能阻止大脑中的多巴胺酶降解多巴胺。MAO-B抑制剂通过抑制这种酶发挥作用,从而提高多巴胺水平,帮助减轻运动症状,如肌肉运动障碍和肌肉僵硬。除了对多巴胺水平有影响外,MAO-B 抑制剂还可能具有神经保护特性。研究表明,这些抑制剂可以保护神经元免受多巴胺分解产生的有害副产品(如二羟基乙醛和过氧化氢)的伤害。这种神经保护作用有可能减缓帕金森氏症的进展并防止神经元受损。MAO-B 抑制剂对治疗晚期和早期帕金森病都很有效。建议将它们作为早期帕金森病患者的初始治疗药物,也可作为晚期帕金森病患者的辅助治疗药物,以协助控制运动并发症。此外,MAO-B 抑制剂还有望治疗帕金森病的非运动症状,如疲劳和睡眠障碍。MAO-B抑制剂是治疗帕金森病的一类重要药物,既能缓解症状,又有潜在的疾病改变作用。目前对MAO-B抑制剂的研发目标是提高其安全性和选择性,从而改进帕金森病和其他神经退行性疾病的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信